UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
_______________________________
(Exact name of registrant as specified in its charter)
_______________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
_______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On August 7, 2023, the Company issued a press release (the “Press Release”) announcing its financial results for the second quarter ended June 30, 2023. A copy of the Press Release is attached as Exhibit 99.1 to this current report on Form 8-K.
The information under Item 2.02 in this current report on Form 8-K and the related information in the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
(d) Exhibits
| Exhibit Number | Description | |
| 99.1 | Press Release dated August 7, 2023 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Shockwave Medical, Inc. | ||
| Date: August 7, 2023 | By: | /s/ Daniel K. Puckett |
| Daniel K. Puckett | ||
| Chief Financial Officer | ||
EXHIBIT 99.1
Shockwave Medical Reports Second Quarter 2023 Financial Results
SANTA CLARA, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended June 30, 2023.
Recent Highlights
- Recognized revenue of $180.2 million for the second quarter of 2023, representing an increase of 49% from the same period in 2022
- As part of the Fiscal Year 2024 Medicare Hospital Inpatient Prospective Payment System (IPPS) final rule, the Centers for Medicare & Medicaid Services (CMS) created three new coronary IVL-specific MS-DRGs, which will become effective October 1, 2023. These new codes are associated with higher payments than the MS-DRG payments for other Percutaneous Coronary Intervention (PCI) procedures
- Announced the full commercial availability of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) Catheter to treat severely calcified coronary artery disease in select international markets
- Initiated enrollment in EMPOWER CAD, the first prospective, all-female study of percutaneous coronary intervention, seeking to confirm the benefits of coronary IVL in female patients with calcified lesions, a patient population that historically has experienced less favorable clinical outcomes with traditional therapies compared with male patients
- Closed the acquisition of Neovasc and commenced the integration into Shockwave
“Our teams throughout the Shockwave organization continue to execute at the highest level, enabling us to offer an expanding range of products to meet the needs of our customers across the globe,” said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. “The consistent growth across our business is a testament to the need for our novel products and we look forward to continuing to provide innovative solutions to improve outcomes for patients suffering from cardiovascular diseases.”
Second Quarter 2023 Financial Results
Revenue for the second quarter ended June 30, 2023, was $180.2 million, a 49% increase from $120.7 million in the same period of 2022. The growth was primarily driven by an increase in the purchase volume of our catheters in both the United States and internationally.
Gross profit for the second quarter of 2023 was $155.7 million compared to $104.0 million for the second quarter of 2022. Gross margin percentage was 86% for the three months ended June 30, 2023, which was unchanged from the gross margin percentage for the three months ended June 30, 2022.
Total operating expenses for the second quarter of 2023 were $123.3 million, a 66% increase from $74.4 million in the second quarter of 2022. The increase was primarily driven by sales force expansion, higher headcount to support the growth of the business, and acquisition-related expenses associated with the acquisition of Neovasc.
Net income for the second quarter of 2023 was $28.9 million, compared to net income of $25.6 million in the same period of 2022. Basic and diluted net income per share for the period was $0.79 and $0.76, respectively.
Cash, cash equivalents and short-term investments totaled $258.6 million as of June 30, 2023.
2023 Financial Guidance
Shockwave Medical projects revenue for the full year 2023 to range from $725 million to $730 million, which represents 48% to 49% growth over the Company’s prior year revenue. This compares to previous revenue guidance for the full year of 2023 of $700 million to $720 million.
Conference Call
Shockwave Medical will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on Monday, August 7, 2023, to discuss its second quarter 2023 financial results. The call may be accessed by dialing 877-704-4453 for domestic callers or 201-389-0920 for international callers, using conference ID: 13737256. A live and archived webcast of the event will be available at https://ir.shockwavemedical.com/.
About Shockwave Medical, Inc.
Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave has also recently acquired the Neovasc Reducer, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at www.shockwavemedical.com and www.neovasc.com.
Forward-Looking Statements
This press release contains statements relating to our expectations, projections, beliefs, and prospects, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” and similar expressions, and the negative of these terms. Forward-looking statements in this press release include, but are not limited to, statements regarding our anticipated future operating results and financial position, including for the full year ending December 31, 2023, our business strategy and plans, our objectives for future operations and financial performance and other matters. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware.
Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others: the impact of macroeconomic conditions, including inflation, rising interest rates, the federal budget, instability in the global banking system, and volatile market conditions, geopolitical factors, including the ongoing conflict between Russia and Ukraine and responses thereto, and supply chain disruptions, on our operations, financial results, liquidity, capital resources, expenses, supply chain, manufacturing, research and development activities, clinical trials, and employees; our ability to successfully execute our business and growth strategies; our ability to develop, manufacture, obtain and maintain regulatory approvals for, and market and sell, our products; our expected future growth, including the size and growth potential of the markets for our products; our ability to obtain coverage and reimbursement for procedures performed using our products; our ability to scale our organizational culture; the impact of the development, regulatory approval, efficacy and commercialization of competing products; the loss of key scientific or management personnel; our ability to develop and maintain our corporate infrastructure, including our internal controls; our financial performance and capital requirements; the success of any acquisitions that we make; and our ability to obtain and maintain intellectual property protection for our products, as well as our ability to operate our business without infringing the intellectual property rights of others. These factors, as well as others, are discussed in our filings with the Securities and Exchange Commission (SEC), including in the sections titled “Risk Factors” in our most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, and in our other reports filed with the SEC. Except to the extent required by law, we do not undertake to update any of these forward-looking statements after the date hereof to conform these statements to actual results or revised expectations.
Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com
Investor Contact:
Debbie Kaster
dkaster@shockwavemedical.com
| SHOCKWAVE MEDICAL, INC. | |||||||||||||
| Balance Sheet Data | |||||||||||||
| (in thousands) | |||||||||||||
| June 30, 2023 | December 31, 2022 | ||||||||||||
| (Unaudited) | |||||||||||||
| ASSETS | |||||||||||||
| CURRENT ASSETS: | |||||||||||||
| Cash and cash equivalents | $ | 141,458 | $ | 156,586 | |||||||||
| Short-term investments | 117,131 | 147,907 | |||||||||||
| Accounts receivable, net | 96,562 | 71,366 | |||||||||||
| Inventory | 92,093 | 75,112 | |||||||||||
| Prepaid expenses and other current assets | 9,118 | 8,292 | |||||||||||
| Total current assets | 456,362 | 459,263 | |||||||||||
| Operating lease right-of-use assets | 31,117 | 32,365 | |||||||||||
| Property and equipment, net | 59,803 | 48,152 | |||||||||||
| Equity method investment | 2,543 | 3,512 | |||||||||||
| Intangible assets, net | 94,692 | — | |||||||||||
| Goodwill | 39,789 | — | |||||||||||
| Deferred tax assets | 94,699 | 97,568 | |||||||||||
| Other assets | 7,599 | 5,229 | |||||||||||
| TOTAL ASSETS | $ | 786,604 | $ | 646,089 | |||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||||
| CURRENT LIABILITIES: | |||||||||||||
| Accounts payable | $ | 12,869 | $ | 6,721 | |||||||||
| Accrued liabilities | 65,769 | 55,375 | |||||||||||
| Lease liability, current portion | 1,582 | 1,278 | |||||||||||
| Total current liabilities | 80,220 | 63,374 | |||||||||||
| Lease liability, noncurrent portion | 33,205 | 34,928 | |||||||||||
| Debt, noncurrent portion | 24,266 | 24,198 | |||||||||||
| Related party contract liability, noncurrent portion | 12,273 | 12,273 | |||||||||||
| Deferred tax liabilities | 10,421 | — | |||||||||||
| Other liabilities | 9,307 | — | |||||||||||
| TOTAL LIABILITIES | 169,692 | 134,773 | |||||||||||
| STOCKHOLDERS’ EQUITY: | |||||||||||||
| Preferred stock | — | — | |||||||||||
| Common stock | 37 | 36 | |||||||||||
| Additional paid-in capital | 586,092 | 548,960 | |||||||||||
| Accumulated other comprehensive loss | (391) | (867) | |||||||||||
| Retained earnings (accumulated deficit) | 31,174 | (36,813) | |||||||||||
| TOTAL STOCKHOLDERS’ EQUITY | 616,912 | 511,316 | |||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 786,604 | $ | 646,089 | |||||||||
| SHOCKWAVE MEDICAL, INC. | ||||||||||||||||
| Statement of Operations Data | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||
| Revenue: | ||||||||||||||||
| Product revenue | $ | 180,165 | $ | 120,746 | $ | 341,231 | $ | 214,377 | ||||||||
| Cost of revenue: | ||||||||||||||||
| Cost of product revenue | 24,493 | 16,730 | 45,559 | 29,620 | ||||||||||||
| Gross profit | 155,672 | 104,016 | 295,672 | 184,757 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 36,829 | 20,760 | 63,800 | 37,779 | ||||||||||||
| Sales and marketing | 56,738 | 40,515 | 110,749 | 76,476 | ||||||||||||
| General and administrative | 29,731 | 13,165 | 48,935 | 25,554 | ||||||||||||
| Total operating expenses | 123,298 | 74,440 | 223,484 | 139,809 | ||||||||||||
| Income from operations | 32,374 | 29,576 | 72,188 | 44,948 | ||||||||||||
| Loss from equity method investment | (146) | (1,464) | (969) | (1,511) | ||||||||||||
| Interest expense | (810) | (304) | (1,446) | (601) | ||||||||||||
| Other income (expense), net | 1,586 | (1,473) | 3,968 | (1,783) | ||||||||||||
| Net income before taxes | 33,004 | 26,335 | 73,741 | 41,053 | ||||||||||||
| Income tax provision | 4,142 | 774 | 5,754 | 971 | ||||||||||||
| Net income | $ | 28,862 | $ | 25,561 | $ | 67,987 | $ | 40,082 | ||||||||
| Net income per share, basic | $ | 0.79 | $ | 0.71 | $ | 1.86 | $ | 1.12 | ||||||||
| Net income per share, diluted | $ | 0.76 | $ | 0.68 | $ | 1.78 | $ | 1.06 | ||||||||
| Shares used in computing net income per share, basic | 36,663,327 | 35,825,947 | 36,545,948 | 35,707,301 | ||||||||||||
| Shares used in computing net income per share, diluted | 38,226,153 | 37,690,094 | 38,139,948 | 37,690,320 | ||||||||||||